Radiotherapy for the management of renal medullary carcinoma
Renal medullary carcinoma (RMC) is a rare and aggressive cancer [...]
NICE approves cabozantinib plus nivolumab for advanced kidney cancer
The National Institute for Health and Care Excellence (NICE) has approved the [...]
PRISM study highlights possibility of reducing dose of immunotherapy
The CheckMate-214 clinical trial was the first study to show [...]
Summary of kidney cancer highlights from ASCO GU 2024
This year’s American Society of Clinical Oncology Genitourinary Cancers (ASCO [...]
Lenvatinib plus pembrolizumab for advanced kidney cancer
The final survival information from the phase 3 CLEAR study [...]
Patient’s perspective on pembrolizumab/lenvatinib for kidney cancer
In 2009, Cesar Fuentes was first diagnosed with kidney cancer [...]
New treatment, zanzalintinib, for advanced kidney cancer
A recent clinical trial looked at a new anti-cancer medication [...]
Treatment of translocation kidney cancer
Translocation kidney cancer is a rare type of kidney cancer [...]
Real world treatment of advanced kidney cancer
Nearly 30% of new kidney cancer cases are diagnosed at [...]
ESMO 2023: Does stopping VEGFR TKI treatment and continuing immunotherapy influence the survival of patients on combination therapy?
In many countries, combinations of VEGFR TKI anti-cancer mediations plus [...]
